p.81 抽出テキスト

infective endocarditis: a systematic review and aggregation of prediction models. Clin Microbiol Infect 2021;27:1422–1430. https://doi.org/10.1016/j.cmi.2021.05.051 257. Hoiby N, Ciofu O, Johansen HK, Song Z-J, Moser C, Jensen PO, et al. The clinical impact of bacterial biofilms. Int J Oral Sci 2011;3:55–65. https://doi.org/10.4248/ IJOS11026 258. Funane K, Tanaka Y, Hosaka T, Murakami K, Miyazaki T, Shiwa Y, et al. Combined drug resistance mutations substantially enhance enzyme production in paenibacillus agaridevorans. J Bacteriol 2018;200:e00188-18. https://doi.org/10.1128/JB.00188-18 259. Knudsen GM, Ng Y, Gram L. Survival of bactericidal antibiotic treatment by a persister subpopulation of Listeria monocytogenes. Appl Environ Microbiol 2013;79:7390–7397. https://doi.org/10.1128/AEM.02184-13 260. Le Bot A, Lecomte R, Gazeau P, Benezit F, Arvieux C, Ansart S, et al. Is rifampin use associated with better outcome in staphylococcal prosthetic valve endocarditis? A multicenter retrospective study. Clin Infect Dis 2021;72:e249–e255. https://doi.org/ 10.1093/cid/ciaa1040 261. Shrestha NK, Shah SY, Wang H, Hussain ST, Pettersson GB, Nowacki AS, et al. Rifampin for surgically treated staphylococcal infective endocarditis: a propensity score-adjusted cohort study. Ann Thorac Surg 2016;101:2243–2250. https://doi.org/ 10.1016/j.athoracsur.2015.11.015 262. Marti-Carvajal AJ, Dayer M, Conterno LO, Gonzalez Garay AG, Marti-Amarista CE. A comparison of different antibiotic regimens for the treatment of infective endocarditis. Cochrane Database Syst Rev 2020;5:CD009880. https://doi.org/10.1002/14651858. CD009880.pub3 263. Tissot-Dupont H, Casalta JP, Gouriet F, Hubert S, Salaun E, Habib G, et al. International experts’ practice in the antibiotic therapy of infective endocarditis is not following the guidelines. Clin Microbiol Infect 2017;23:736–739. https://doi.org/10.1016/j.cmi.2017. 03.007 264. Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009;48:713–721. https://doi.org/10.1086/597031 265. Pericas JM, Nathavitharana R, Garcia-de-la-Maria C, Falces C, Ambrosioni J, Almela M, et al. Endocarditis caused by highly penicillin-resistant viridans group streptococci: still room for vancomycin-based regimens. Antimicrob Agents Chemother 2019;63: e00516-19. https://doi.org/10.1128/AAC.00516-19 266. Dahl A, Rasmussen RV, Bundgaard H, Hassager C, Bruun LE, Lauridsen TK, et al. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. Circulation 2013;127:1810–1817. https://doi.org/10.1161/CIRCULATIONAHA.112.001170 267. Miro JM, Garcia-de-la-Maria C, Armero Y, Soy D, Moreno A, del Rio A, et al. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:4172–4177. https://doi.org/10.1128/AAC. 00051-09 268. Garrigos C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, et al. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013;57:606–610. https://doi.org/10.1128/AAC.01570- 12 269. Peghin M, Russo A, Givone F, Ingani M, Graziano E, Bassetti M. Should high-dose daptomycin be an alternative treatment regimen for enterococcal endocarditis? Infect Dis Ther 2019;8:695–702. https://doi.org/10.1007/s40121-019-00261-w 270. Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother 2013;68:2921–2926. https://doi.org/ 10.1093/jac/dkt294 271. Carugati M, Bayer AS, Miro JM, Park LP, Guimaraes AC, Skoutelis A, et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. Antimicrob Agents Chemother 2013;57: 6213–6222. https://doi.org/10.1128/AAC.01563-13 272. Pujol M, Miro JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, et al. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial. Clin Infect Dis 2021;72: 1517–1525. https://doi.org/10.1093/cid/ciaa1081 273. West KA, Sheeti A, Tamura MacKay K, Forrest GN. Eosinophilic syndromes associated with daptomycin use: re-exposure hypersensitivity pneumonitis and prior peripheral eosinophilia. Open Forum Infect Dis 2022;9:ofac065. https://doi.org/10.1093/ ofid/ofac065 274. Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Davila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by Gram-positive cocci. Ann Clin Microbiol Antimicrob 2019;18:30. https://doi.org/10.1186/s12941-019-0329-6 275. Spaziante M, Franchi C, Taliani G, D’Avolio A, Pietropaolo V, Biliotti E, et al. Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report. Open Forum Infect Dis 2019;6:ofz427. https://doi.org/10.1093/ofid/ofz427 276. Abranches J, Zeng L, Kajfasz JK, Palmer SR, Chakraborty B, Wen ZT, et al. Biology of oral streptococci. Microbiol Spectr 2018;6. https://doi.org/10.1128/microbiolspec. GPP3-0042-2018 277. Westling K, Aufwerber E, Ekdahl C, Friman G, Gardlund B, Julander I, et al. Swedish guidelines for diagnosis and treatment of infective endocarditis. Scand J Infect Dis 2007;39:929–946. https://doi.org/10.1080/00365540701534517 278. Gould FK, Denning DW, Elliott TS, Foweraker J, Perry JD, Prendergast BD, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the working party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012;67:269–289. https://doi.org/10.1093/jac/dkr450 279. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015;132:1435–1486. https://doi.org/10.1161/CIR. 0000000000000296 280. Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. JAMA 1992;267:264–267. https://doi.org/10.1001/jama. 1992.03480020074034 281. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995;21:1406–1410. https://doi.org/10.1093/clinids/21.6.1406 282. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998;27: 1470–1474. https://doi.org/10.1086/515038 283. Cremieux AC, Maziere B, Vallois JM, Ottaviani M, Azancot A, Raffoul H, et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989;159:938–944. https://doi.org/10.1093/infdis/159.5.938 284. Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother 1996;38:507–521. https://doi.org/10.1093/ jac/38.3.507 285. Moet GJ, Dowzicky MJ, Jones RN. Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci. Diagn Microbiol Infect Dis 2007;57: 333–336. https://doi.org/10.1016/j.diagmicrobio.2006.08.001 286. Shelburne SA 3rd, Greenberg SB, Aslam S, Tweardy DJ. Successful ceftriaxone therapy of endocarditis due to penicillin non-susceptible viridans streptococci. J Infect 2007;54: e99–e101. https://doi.org/10.1016/j.jinf.2006.05.010 287. Hsu RB, Lin FY. Effect of penicillin resistance on presentation and outcome of nonenterococcal streptococcal infective endocarditis. Cardiology 2006;105:234–239. https://doi.org/10.1159/000091821 288. Knoll B, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Infective endocarditis due to penicillin-resistant viridans group streptococci. Clin Infect Dis 2007;44: 1585–1592. https://doi.org/10.1086/518174 289. Levy CS, Kogulan P, Gill VJ, Croxton MB, Kane JG, Lucey DR. Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin Infect Dis 2001;33:577–579. https://doi.org/10.1086/321910 290. Pilmis B, Lourtet-Hascoet J, Barraud O, Piau C, Isnard C, Hery-Arnaud G, et al. Be careful about MICs to amoxicillin for patients with streptococci-related infective endocarditis. Int J Antimicrob Agents 2019;53:850–854. https://doi.org/10.1016/j.ijantimicag. 2019.03.002 291. Matsuo T, Mori N, Sakurai A, Kanie T, Mikami Y, Uehara Y, et al. Effectiveness of daptomycin against infective endocarditis caused by highly penicillin-resistant viridans group streptococci. IDCases 2021;24:e01113. https://doi.org/10.1016/j.idcr.2021. e01113 292. Hook EW 3rd, Johnson WD Jr. Vancomycin therapy of bacterial endocarditis. Am J Med 1978;65:411–415. https://doi.org/10.1016/0002-9343(78)90766-0 293. Beraud G, Tubiana S, Erpelding ML, Le Moing V, Chirouze C, Gorenne I, et al. Combined bacterial meningitis and infective endocarditis: when should we search for the other when either one is diagnosed? Infect Dis Ther 2022;11:1521–1540. https://doi.org/10.1007/s40121-022-00651-7 294. de Egea V, Munoz P, Valerio M, de Alarcon A, Lepe JA, Miro JM, et al. Characteristics and outcome of Streptococcus pneumoniae endocarditis in the xxi century: a systematic review of 111 cases (2000–2013). Medicine (Baltimore) 2015;94:e1562. https://doi.org/ 10.1097/MD.0000000000001562 295. Martinez E, Miro JM, Almirante B, Aguado JM, Fernandez-Viladrich P, Fernandez-Guerrero ML, et al. Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. Clin Infect Dis 2002;35:130–139. https://doi.org/10.1086/341024 296. Perier A, Puyade M, Revest M, Tattevin P, Bernard L, Lemaignen A, et al. Prognosis of Streptococcus pneumoniae endocarditis in France, a multicenter observational study (2000–2015). Int J Cardiol 2019;288:102–106. https://doi.org/10.1016/j.ijcard.2019. 04.048 Downloaded from academic.oup.com/eurheartj/article/44/39/3948/7243107 by guest on 07 October 2026